Chemotherapy

Lancet

Volumn 349, Issue SUPPL.2, 1997, Pages

  Pinedo, Herbert M ^a   Giaccone, Giuseppe ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANALGESIC AGENT; ANTIANDROGEN; ANTIEMETIC AGENT; ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; CLADRIBINE; COLONY STIMULATING FACTOR; CYCLOPHOSPHAMIDE; DAUNORUBICIN; DOCETAXEL; FLUDARABINE; FLUOROURACIL; GEMCITABINE; GONADORELIN AGONIST; IDARUBICIN; IFOSFAMIDE; IRINOTECAN; MORPHINE; NAVELBINE; PACLITAXEL; RALTITREXED; RETINOIC ACID; SEROTONIN 1 ANTAGONIST; STEROID; TAMOXIFEN; THROMBOPOIETIN; TOPOTECAN;

BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; CANCER; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER SURVIVAL; CARDIOTOXICITY; DIARRHEA; DRUG EFFICACY; DRUG HYPERSENSITIVITY; FLU LIKE SYNDROME; FLUID RETENTION; HUMAN; IMMUNE DEFICIENCY; LEUKEMIA; LIVER TOXICITY; LYMPHOCYTOPENIA; LYMPHOMA; MULTIDRUG RESISTANCE; NEUROTOXICITY; NEUTROPENIA; ORAL DRUG ADMINISTRATION; PAIN; PRIORITY JOURNAL; SHORT SURVEY; THROMBOCYTOPENIA; VOMITING;

EID: 0031008132     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0140-6736(97)90012-x     Document Type: Article

References (24)

1. Löwenberg B. Acute myelogenous leukemia and myelodysplasia. In: Löwenberg B, ed. Baillière's clinical haematology. London:Baillière Tindall, 1996: 9: 1-203.
2. Pinedo HM, Longo DL, Chabner BA, eds. Cancer chemotherapy and biological response modifiers. Amsterdam: Elsevier Annual 17 (in press).
3. Gelmon K. The taxoids: paclitaxel and docetaxel. Lancet 1994; 344: 1267-72.
4. Gianni L, Munzone E, Capri G, et al. Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study. J Clin Oncol 1995; 13: 2688-99.
5. Peters GJ, Ackland SP. New antimetabolites in preclinical and clinical development. Exp Opin Invest Drugs 1996; 5: 637-79.
6. Burris HA, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer a randomized trial. J Clin Oncol (in press).
7. Dancey J, Eisenhauer EA. Current perspectives on camptothecins in cancer treatment. Br J Cancer 1996; 74: 327-28.
8. Pinedo HM, Van Groeningen CJ. Vinorelbine: a horse of a different color? J Clin Oncol 1994; 9: 1745-47.
9. Chomienne C, Fenaux P, Degos L. Retinoid differentiation therapy in promyelocytic leukemia. FASEB J 1996; 10: 1025-30.
10. Bishop JF, Matthews JP, Young GA, et al. A randomized study of high-dose cytarabine in induction in acute myeloid leukemia. Blood 1996; 87: 1710-17.
11. Attal M, Harousseau JL, Stoppa AM, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Engl J Med 1996; 335: 91-97.
12. Löwenberg B. Postremission treatment of acute myelogenous leukemia. N Engl J Med 1995; 332: 260-62.
13. Margolin K, Doroshow JH, Ahn Ch, et al. Treatment of germ cell cancer with two cycles of high-dose ifosfamide, carboplatin, and etoposide with autologous stem-cell support. J Clin Oncol 1996; 14: 2631-37.
14. Meta-Analysis Group in Cancer. Reappraisal of hepatic arterial infusion in the treatment of nonresectable liver metastases from colorectal cancer. J Natl Cancer Inst 1996; 88: 252-58.
15. Alberts DS, Liu PY, Hannigan EV, et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med 1996; 335: 1950-55.
16. Eggermont AMM, Schraffordt Koops H, Liénard D, et al. Isolated limb perfusion with high-dose tumor necrosis factor-α in combination with interferon-γ and melphalan for nonresectable extremity soft tissue sarcomas: a multicenter trial. J Clin Oncol 1996; 14: 2653-65.
17. Izquierdo MA, Van der Zee AGJ, Vermorken JB, et al. Drug resistance-associated marker LRP for prediction of response to chemotherapy and prognosis in advanced ovarian carcinoma. J Natl Cancer Inst 1995; 87: 1230-37.
18. Nishimura T, Newkirk K, Sessions RB, et al. Immunohistochemical staining for glutathione S-transferase predicts response to platinum-based chemotherapy in head and neck cancer. Clin Cancer Res 1996; 2: 1859-65.
19. Peters GJ, Van der Wilt CL, Van Groeningen CJ, et al. Thymidylate synthase inhibition after administration of 5-fluorouracil with or without leucovorin; implications for treatment with 5-fluorouracil. J Clin Oncol 1994; 12: 2035-42.
20. Pinedo HM and Giaccone G. P-Glycoprotein - a marker of cancer-cell behavior. N Engl J Med 1995; 333: 1417-19.
21. Harris CC. Structure and function of the p53 tumor suppressor gene: clues for rational cancer therapeutic strategies. J Natl Cancer Inst 1996; 88: 1442-55.
22. Swedish Breast Cancer Cooperative Group. Randomized trial of two versus five years of adjuvant tamoxifen for postmenopausal early stage breast cancer. J Natl Cancer Inst 1996; 88: 1543-49.
23. 3) antagonists in the prevention of emesis caused by anticancer therapy. Biochem Pharmacol 1996; 52: 685-92.
24. Hortobagyi GN, Theriault RL, Porter L et al. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. N Engl J Med 1996; 335: 1785-91.